| Tue, Dec 1, 2009 | | • | Pluristem Therapeutics Completes Dosing of First Group of Patients in Europe With Placenta-Derived Cell Therapy Product PLX-PAD in Phase I Clinical Trial for Treatment of Critical Limb Ischemia (CLI)
GlobeNewswire (Tue 8:00am)
| | Thu, Nov 19, 2009 | | • | Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France
Business Wire (Thu, Nov 19)
| | Tue, Nov 17, 2009 | | • | PLURISTEM THERAPEUTICS INC Financials
EDGAR Online Financials (Tue, Nov 17)
| | • | Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD
Business Wire (Tue, Nov 17)
| | Thu, Nov 12, 2009 | | • | PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 12)
| | Wed, Nov 11, 2009 | | • | Can Stem Cells Put an End To Paralysis?
Indie Research (Wed, Nov 11)
| | Tue, Oct 20, 2009 | | • | Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine
Business Wire (Tue, Oct 20)
| | Wed, Oct 14, 2009 | | • | Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summit
Business Wire (Wed, Oct 14)
| | Fri, Oct 9, 2009 | | • | Another Coin-Flip Bet on a Stem Cell Drug
Indie Research (Fri, Oct 9)
| | Tue, Oct 6, 2009 | | • | PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
EDGAR Online (Tue, Oct 6)
| | • | Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering
Business Wire (Tue, Oct 6)
| | Thu, Oct 1, 2009 | | • | Pluristem Provides Disclosure Pursuant to NASDAQ Marketplace Rule 5250(b)(2)
GlobeNewswire (Thu, Oct 1)
| | Wed, Sep 30, 2009 | | • | Stem Cell Summit Can't Excite Investors
Indie Research (Wed, Sep 30)
| | Tue, Sep 29, 2009 | | • | Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential Conference 2009: Facing Tomorrow, Based on the Company's Proprietary Technology and the Potential to Shape The Future of the Stem Cell Industry
Business Wire (Tue, Sep 29)
| | Wed, Sep 23, 2009 | | • | PLURISTEM THERAPEUTICS INC Files SEC form 10-K, Annual Report
EDGAR Online (Wed, Sep 23)
| | • | Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Business Wire (Wed, Sep 23)
| | Fri, Sep 11, 2009 | | • | Investors Won Big in This Week's Top Sectors
Indie Research (Fri, Sep 11)
| | Thu, Sep 10, 2009 | | • | Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Business Wire (Thu, Sep 10)
| | Wed, Sep 9, 2009 | | • | Pluristem Therapeutics Will Present Its Unique Placenta Derived Stem Cell Therapy Approach at Charles River Biotech Symposium
Business Wire (Wed, Sep 9)
| | Tue, Sep 8, 2009 | | • | This 10-Bagger's Still Got Legs
Indie Research (Tue, Sep 8)
|
Add PSTI News to My Yahoo!:
 
| |
|
1.23% Nasdaq 0.00%
Headlines
